Posted by: admin Categories: Genetics

Revolution Investing. Opinion: A new addition to the portfolio: CRISPR Therapeutics. Published: April 8, 2020 at 1:38 p.m. ET ...

Source link

« Swedish hospitals abandon trial of promising malaria drug chloroquine for coronavirus patients …

Researchers Plan to Evaluate CORVax12 Vaccine in Phase I Clinical Trial for COVID-19 »

Latest Tweets

Update: Each purchase of Breathing+ will now include three machine washable mouthpieces. Previous buyers will be su… twitter.com/i/web/status/13328…
November 28, 2020 10:41 pm
Update: We moved servers + relocated all our games to our servers, please be patient while google reviews all that… twitter.com/i/web/status/13237…
November 3, 2020 7:31 pm
Registration and all functionalities at breathinglabs.com (and in our iOS and Android games) are fixed and fu… twitter.com/i/web/status/12407…
March 19, 2020 10:50 pm
We are back in stock with Breathing+, currently searching for VR supplier, and setting up mass production for toys… twitter.com/i/web/status/11717…
September 11, 2019 12:00 pm
BREAKING: Nintendo Co. Ltd (Japan) is implementing Breathing Games by @breathinglabs in FDA approved clinical trial… twitter.com/i/web/status/11580…
August 4, 2019 5:55 pm
Notice to b2b partners: we are running late with some minor upgrade-> briefly running out of stock -> retail and b2… twitter.com/i/web/status/11337…
May 29, 2019 1:48 pm
BREAKING: Our product BREATHING+ shows significant and reliable diagnostic value in comparison to standard spiromet… twitter.com/i/web/status/10812…
January 4, 2019 4:02 pm
Video: Resperate company endorses pursed lip breathing and shows pulmonary function improvement in real time.… twitter.com/i/web/status/10711…
December 7, 2018 8:51 pm
Notice on limited availability during July 25th and August 5th: Help and support will be mostly functional via supp… twitter.com/i/web/status/10148…
July 5, 2018 1:41 pm

Home

How To Start

Q&A

Login

Opinion: A new addition to the portfolio: CRISPR Therapeutics

Latest Tweets

ABOUT

TECHNOLOGY

CLINICAL USE

COLLABORATION

REFERENCE

Home

How To Start

Products

Breathing+ Package

Toys Package

Q&A

Login

Opinion: A new addition to the portfolio: CRISPR Therapeutics

You may also like...

Trouble understanding “Join” operator of NCBI

CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress

(2021-2026) Gene Editing Technology Market Research Region Wise Analysis of Top Players In Market By Its Types And Application

Latest Tweets

ABOUT

TECHNOLOGY

CLINICAL USE

COLLABORATION

REFERENCE